LivaNova’s (LIVN) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research note released on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $75.00 target price on the stock.

A number of other equities analysts have also recently issued reports on the company. The Goldman Sachs Group initiated coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird boosted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Stifel Nicolaus increased their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LivaNova has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Price Performance

LIVN traded down $0.74 on Thursday, reaching $50.88. The company had a trading volume of 136,367 shares, compared to its average volume of 620,196. LivaNova has a 52-week low of $42.75 and a 52-week high of $64.47. The company has a market cap of $2.76 billion, a price-to-earnings ratio of 122.90 and a beta of 1.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.37. The business has a 50 day simple moving average of $51.04 and a 200 day simple moving average of $53.14.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. The company had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. As a group, sell-side analysts anticipate that LivaNova will post 2.58 EPS for the current year.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently modified their holdings of LIVN. Emerald Advisers LLC grew its position in LivaNova by 2.1% in the 3rd quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock worth $36,542,000 after purchasing an additional 14,302 shares during the period. abrdn plc lifted its stake in shares of LivaNova by 43.8% in the 3rd quarter. abrdn plc now owns 232,025 shares of the company’s stock valued at $12,191,000 after purchasing an additional 70,618 shares during the last quarter. State of Alaska Department of Revenue raised its stake in shares of LivaNova by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock valued at $328,000 after acquiring an additional 425 shares during the period. Allspring Global Investments Holdings LLC raised its position in LivaNova by 3.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock worth $41,889,000 after purchasing an additional 25,277 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. lifted its position in shares of LivaNova by 11.8% during the third quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 19,000 shares of the company’s stock worth $998,000 after purchasing an additional 2,000 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.